Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mote Marine Laboratory Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and 1 distinct art unit, showing a highly concentrated prosecution effort. This indicates that the company's current patent activity is focused on a specific technical topic within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the portfolio is SCOTLAND, REBECCA LYNN, who is overseeing the 1 pending office action. The busiest examiner pending count of 1 matches the total number of pending office actions, meaning there are no other active cases being reviewed by other examiners. This 1 point of contact allows for a direct and focused prosecution path through the patent office.
For practitioners, this data suggests that the outcome of the company's current patent efforts depends entirely on the interaction with SCOTLAND, REBECCA LYNN. With 1 pending office action, the portfolio is in a state of minimal active expansion. The alignment of 1 distinct examiner and 1 distinct art unit simplifies the administrative task of tracking deadlines for this Biotechnology & Pharmaceuticals application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18814440 | HARMFUL ALGAL BLOOM MITIGATION | SCOTLAND, REBECCA LYNN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18814440 | HARMFUL ALGAL BLOOM MITIGATION | SCOTLAND, REBECCA LYNN | 1615 | §103§112Other | Non-Final OA | — | Pending | Aug 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMote Marine Laboratory Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Rebecca Lynn Scotland has the most, with 1 of Mote Marine Laboratory Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.